IONIQ ProLung Test™ recognized with Global Innovation & Excellence award for “Best Lung Cancer Detection and Diagnosis Solutions Firm – 2020” by CorporateLiveWire
IONIQ Sciences is delighted to announce its IONIQ ProLung Test™ was recognized with the Global Innovation & Excellence award for “Best Lung Cancer Detection and Diagnosis Solutions Firm – 2020” by CorporateLiveWire. This prestigious industry award comes on the heels of the US FDA designating the IONIQ ProLung Test a Breakthrough Device earlier this year. IONIQ’s first planned product will be the IONIQ ProLung Test, which will ultimately underpin a Multi-Cancer Screen.
By operating at the confluence of Electrical Impedance Analytics (EIA) and Artificial Intelligence, IONIQ’s vision is to dramatically improve the cancer landscape with a modern solution for early detection of multiple cancers thereby expanding the therapeutic window, significantly improving survivability, and reducing the cost of healthcare.